We would love to hear your thoughts about our site and services, please take our survey here.
Aquae, will we take MIKODX out of his misery?; your calculation show him how. Compound interest isn't exactly simple! Let's give him the formula around which your numbers play out. P X (1+rate). If it's for other than a single period it's enhanced to the power of the term. P of course is the principle. The "1" in the formula is what moves us away from MIK's all-too-simple 'multiple' factor; it gives us, instead, the 'percentage increase'. So 22,000 X (1+250%) gives us 22,000 + 55,000 = 77,000. Simple.
And, as you say, Aquea, in the order of things nothing as dramatic as the cold statistic might have one believe. It's merely relative.
One
Yes Odysseus; and I was told to F*** off for expressing similar sentiments. All of October we were on receiving end of a hyped countdown to launch day (not by management) when our US partner would blow the lights out. Nothing happens and you're the bad guy for pointing the finger at the rampers. Meantime the market shows its disappointment. Like you, I'll be staying put; just prefer if a more balanced lead in had been allowed. And we'd still be at mid-Sixties but happy to be there, awaiting developments, including some sort of profile in U.S. following launch on "Psoriasis Day."
thanks Elrico; I'll chill.
I see mention in this exchange of "see bottom of the page" in relation to NPF home page. Bottom of page has headline about advance online information - this leads to next page at bottom of which is piece about the gut and psoriasis - most promising. Does Axisbiotix get a mention in the "see bottom of page" link above?
and haven't you a way words words, Madabout? Earlier speculation leaves question mark as to where your "thousands" count starts. Have some iffy neighbours myself Kilgeever - maybe I, too, should humour Madabout? Aside from all of this, I'm a long term holder.
in your camp Giraffe; what's not surprising is that a market that has factored in the daily count-down to launch date, the speculation as regards massive registration numbers, would show initial disappointment at a lack of enthusiasm suggested by further speculation that a major email invitation drew in 90 subscribers initially. The core message/product hasn't altered and we should let these speak for themselves, as I expect them to. Calling attention to £45K p.a. revenue stream perhaps did more harm than good.